ASCO GI 2016
Results from an open-label, randomized phase 3 trial evaluating the effects of panitumumab plus best supportive care versus best supportive care alone in chemorefractory, wild-type KRAS exon 2 and wild-type RAS metastatic colorectal cancer.
Results from a phase 1b study of the cancer stem-cell pathway inhibitor BBI608 in combination with FOLFIRI Â± bevacizumab in patients with advanced colorectal cancer.
NEO-102, an Anti-MUC5AC Monoclonal Antibody, in Chemotherapy-Refractory Metastatic Colorectal Cancer
Initial results from a phase 2 open-label study of NEO-102, a novel chimeric monoclonal antibody targeting a variant of MUC5AC, in patients with chemotherapy-refractory metastatic colorectal cancer.
Results from STEAM, an open-label, randomized, phase 2 study of sequential versus concurrent FOLFOXIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer.
Results from the phase 1b JAVELIN study of the antiâ€“PD-L1 monoclonal antibody avelumab in patients with advanced gastric or gastroesophageal junction cancer, stratified based on the level of PD-L1 expression.
Results of an open-label phase 1/2 study evaluating the safety and efficacy of nivolumab monotherapy for patients with advanced gastroesophageal or gastric cancer.
Results of the phase 1b KEYNOTE-028 study of pembrolizumab in PD-L1+ advanced esophageal carcinoma.
Investigation of the role of the mTOR pathway on the stemness of a putative cancer stem- cell population in esophageal cancer.
Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Results from RAINBOW, a randomized phase 3 trial of the safety and efficacy of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.
An in vitro study to determine whether inactivation of the Notch and wnt-beta-catenin pathways is crucial for cancer stem-cell development and if such a therapeutic approach with a Î³-secretase inhibitor would be effective in treating patients with gastric cancer.